Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 13/20 | 0.55 |
| ▸ | TAS1R1 | Q7RTX1 | 12/20 | 0.55 |
| ▸ | TAS1R2 | Q8TE23 | 10/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248958 | 0.98 | TAS1R3 (0.52) | TAS1R3TAS1R1TAS1R2TDP1 | |
| SCHEMBL3231475 | 0.94 | TAS1R3 (0.51) | TAS1R3TAS1R1TAS1R2TDP1 | |
| SCHEMBL4247481 | 0.93 | TAS1R3 (0.52) | TAS1R3TAS1R1TAS1R2TDP1 | |
| SCHEMBL4245818 | 0.91 | TAS1R3 (0.49) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL4251680 | 0.89 | TDP1 (0.45) | TAS1R3TAS1R1TDP1POLB | |
| SCHEMBL4249013 | 0.88 | TDP1 (0.44) | TAS1R3TAS1R1TAS1R2TDP1POLB | |
| SCHEMBL4248615 | 0.87 | MEN1 (0.54) | TDP1POLBALDH1A1 | |
| SCHEMBL4248628 | 0.87 | TAS1R3 (0.64) | TAS1R3TAS1R1TAS1R2KDM4EALDH1A1 | |
| SCHEMBL4240828 | 0.87 | TAS1R3 (0.64) | TAS1R3TAS1R1TAS1R2KDM4EALDH1A1 | |
| SCHEMBL4247590 | 0.87 | TAS1R3 (0.64) | TAS1R3TAS1R1TAS1R2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902400-B2 | N-(1,1-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; N-(2,2-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; controlling plant diseases | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7902400-B2 | N-(1,1-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; N-(2,2-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; controlling plant diseases | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7902400-B2 | N-(1,1-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; N-(2,2-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; controlling plant diseases | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20090131531-A1 | Amide Compounds and their Use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131531-A1 | Amide Compounds and their Use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131531-A1 | Amide Compounds and their Use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1940780-A1 | AMIDE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL CO., LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007049728-A1 | AMIDE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131531-A1 | Amide Compounds and their Use | NAT1, ACAT2, NAAA | TAS1R3 1939/4885TAS1R1 885/4885TAS1R2 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.